Lineage Cell Therapeutics Inc.
LCTX | TA
Overview
Corporate Details
- ISIN(s):
- US53566P1093
- LEI:
- Country:
- Israel
- Address:
- Derech Menachem Begin 121, 6701203 Tel Aviv
- Website:
- https://lineagecell.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel allogeneic, or “off-the-shelf,” cell therapies for serious medical conditions. Leveraging its proprietary cell-based technology platform, the company designs, develops, and manufactures specialized human cells derived from pluripotent cell lines. These therapies aim to replace or support cells that are absent or dysfunctional due to degenerative disease, aging, or traumatic injury. The company's pipeline primarily targets neurological and ophthalmic conditions, including spinal cord injuries and degenerative retinal diseases, with the goal of restoring or enhancing patient functional activity.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Lineage Cell Therapeutics Inc..
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-13 11:32 |
Earnings Release
Second Quarter 2025 Financial Results and Provides Business Update
|
English | 69.6 KB | |
| 2025-08-13 11:32 |
Foreign Filer Report
Second Quarter 2025 Financial Results and Provides Business Update
|
English | 36.5 KB | |
| 2025-07-03 15:05 |
Director's Dealing
FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP - Jayasuriya Anula
|
Hebrew (modern) | 117.3 KB | |
| 2025-07-03 15:05 |
Foreign Filer Report
FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP - Jayasuriya Anula
|
English | 36.6 KB | |
| 2025-07-03 15:00 |
Director's Dealing
FORM4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP - Mulroy Michael H.
|
Hebrew (modern) | 117.7 KB | |
| 2025-07-03 15:00 |
Major Shareholding Notification
FORM4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP - Mulroy Michael H.
|
English | 36.5 KB | |
| 2025-07-03 14:55 |
Post-Annual General Meeting Information
FORM 8-K-The Annual Meeting - final voting results
|
Hebrew (modern) | 128.3 KB | |
| 2025-07-03 14:55 |
Declaration of Voting Results & Voting Rights Announcements
FORM 8-K-The Annual Meeting - final voting results
|
English | 36.5 KB | |
| 2025-06-23 20:53 |
Proxy Solicitation & Information Statement
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS To Be Held June 26, 2025
|
English | 2.8 MB | |
| 2025-06-23 20:53 |
Foreign Filer Report
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS To Be Held June 26, 2025
|
English | 36.5 KB | |
| 2025-05-14 12:01 |
Earnings Release
First Quarter 2025 Financial Results and Provides Business Update
|
English | 64.9 KB | |
| 2025-05-14 12:01 |
Report Publication Announcement
First Quarter 2025 Financial Results and Provides Business Update
|
English | 36.5 KB | |
| 2025-05-14 11:23 |
Regulatory News Service
The company's financial results for the First quarter of 2025 were reported abr…
|
Hebrew (modern) | 82.6 KB | |
| 2025-03-11 11:29 |
Earnings Release
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial R…
|
English | 71.6 KB | |
| 2025-03-11 11:29 |
Foreign Filer Report
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial R…
|
English | 36.7 KB |
Automate Your Workflow. Get a real-time feed of all Lineage Cell Therapeutics Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Lineage Cell Therapeutics Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
